Morphasol 4 mg/ml sol. inj. i.v. flac. Bèlgica - francès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

morphasol 4 mg/ml sol. inj. i.v. flac.

animedica-herstellungs gmbh - tartrate de butorphanol 5,83 mg/ml - eq. butorphanol 4 mg/ml - solution injectable - 4 mg/ml - tartrate de butorphanol 5.83 mg/ml - butorphanol - chien; chat

Morphasol 10 mg/ml sol. inj. i.v. flac. Bèlgica - francès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

morphasol 10 mg/ml sol. inj. i.v. flac.

animedica-herstellungs gmbh - tartrate de butorphanol 14,7 mg/ml - eq. butorphanol 10 mg/ml - solution injectable - 10 mg/ml - tartrate de butorphanol 14.7 mg/ml - butorphanol - cheval

Torbugesic Vet 10 mg/ml sol. inj. i.m./i.v./s.c. flac. Bèlgica - francès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

torbugesic vet 10 mg/ml sol. inj. i.m./i.v./s.c. flac.

zoetis belgium sa-nv - tartrate de butorphanol 14,58 mg/ml - eq. butorphanol 10 mg/ml - solution injectable - 10 mg/ml - tartrate de butorphanol 14.58 mg/ml - butorphanol - chien; cheval; chat

PENTASA 4 g, granulés en sachet França - francès - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

pentasa 4 g, granulés en sachet

ferring sas - mésalazine - granulés - 4 g - composition pour un sachet > mésalazine : 4 g - anti-inflammatoire intestinal

Veklury Unió Europea - francès - EMA (European Medicines Agency)

veklury

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Sarclisa Unió Europea - francès - EMA (European Medicines Agency)

sarclisa

sanofi winthrop industrie - isatuximab - le myélome multiple - agents antinéoplasiques - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Regkirona Unió Europea - francès - EMA (European Medicines Agency)

regkirona

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - des sérums et immunoglobulines, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Xevudy Unió Europea - francès - EMA (European Medicines Agency)

xevudy

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - des sérums et immunoglobulines, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.

Evusheld Unió Europea - francès - EMA (European Medicines Agency)

evusheld

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Padcev Unió Europea - francès - EMA (European Medicines Agency)

padcev

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - agents antinéoplasiques - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.